Cover Image
Market Research Report
Product code 
997350

Market Spotlight: Fibromyalgia

Published: | Datamonitor Healthcare | 37 Pages | Delivery time: 1-2 business days

Price

Back to Top
Market Spotlight: Fibromyalgia
Published: March 16, 2021
Datamonitor Healthcare
Content info: 37 Pages
Delivery time: 1-2 business days
  • Description
  • Table of Contents

This Market Spotlight report covers the Fibromyalgia market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, prevalence data, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways:

The approved drugs in the fibromyalgia space target dopamine reuptake, norepinephrine (noradrenaline) reuptake/transporter, serotonin reuptake, and voltage-gated calcium channels. All of the marketed drugs for fibromyalgia are administered via the oral route.

The majority of industry-sponsored drugs in active clinical development for fibromyalgia are in Phase II. Therapies in development for fibromyalgia focus on a wide variety of targets. These drugs are most commonly administered via the oral route.

High-impact upcoming events in the fibromyalgia space comprise topline Phase III trial results for Tonmya, topline Phase II trial results for NYX-2925, and topline Phase IIb trial results for IMC-1.

The overall likelihood of approval of a Phase I pain asset is 5.6%, and the average probability a drug advances from Phase III is 55.9%. Drugs, on average, take 9.5 years from Phase I to approval, compared to 9.8 years in the overall neurology space.

The distribution of clinical trials across Phase I-IV indicates that the majority of trials for fibromyalgia have been in the late phases of development, with 69% of trials in Phase III-IV, and 31% in Phase I-II.

The US has a substantial lead in the number of fibromyalgia clinical trials globally. Germany, Spain, and the UK lead the major European markets, while India has the top spot in Asia.

Clinical trial activity in the fibromyalgia space is dominated by completed trials. Pfizer has the highest number of completed clinical trials for fibromyalgia, with 23 trials.

Pfizer leads industry sponsors with the highest overall number of clinical trials for fibromyalgia, followed by AbbVie.

Product Code: DMKC0206383

TABLE OF CONTENTS

CONTENTS

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

  • Disease definition
  • Symptoms
  • Patient subtypes
  • Risk factors
  • Diagnosis

TREATMENT

  • Pharmacological therapies

EPIDEMIOLOGY

  • Fibromyalgia prevalence

MARKETED DRUGS

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION

  • Tonmya for Fibromyalgia (December 7, 2020)
  • IMC-1 for Fibromyalgia (August 28, 2020)

KEY UPCOMING EVENTS

KEY REGULATORY EVENTS

  • Sawai Claims A First With Japanese Pregabalin Launch

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS

  • Exagen Licenses Ohio State's Fibromyalgia Diagnosis IP

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE

  • Sponsors by status
  • Sponsors by phase

BIBLIOGRAPHY

  • Prescription information

APPENDIX

LIST OF FIGURES

  • Figure 1: Overview of pipeline drugs for fibromyalgia in the US
  • Figure 2: Pipeline drugs for fibromyalgia, by company
  • Figure 3: Pipeline drugs for fibromyalgia, by drug type
  • Figure 4: Pipeline drugs for fibromyalgia, by classification
  • Figure 5: Tonmya for Fibromyalgia (December 7, 2020): Phase III - RELIEF
  • Figure 6: IMC-1 for Fibromyalgia (August 28, 2020): Phase IIa - PRID-201
  • Figure 7: Key upcoming events in fibromyalgia
  • Figure 8: Probability of success in the pain pipeline
  • Figure 9: Clinical trials in fibromyalgia
  • Figure 10: Top 10 drugs for clinical trials in fibromyalgia
  • Figure 11: Top 10 companies for clinical trials in fibromyalgia
  • Figure 12: Trial locations in fibromyalgia
  • Figure 13: Fibromyalgia trials status
  • Figure 14: Fibromyalgia trials sponsors, by phase

LIST OF TABLES

  • Table 1: Marketed drugs for fibromyalgia
  • Table 2: Pipeline drugs for fibromyalgia in the US
  • Table 3: Tonmya for Fibromyalgia (December 7, 2020)
  • Table 4: IMC-1 for Fibromyalgia (August 28, 2020)
  • Table 5: Historical global sales, by drug ($m), 2015-19
  • Table 6: Forecasted global sales, by drug ($m), 2021-25